Table 2

Correlation of baseline biomarker levels with baseline clinical activity measures

BiomarkerPsA durationPsoriasis durationTime from psoriasis to PsAPsoriasis BSAPsoriasis PASISwollen joint count (66)Tender joint count (68)Das28-CRP
CRPr0.070.01−0.040.110.090.120.120.39
p0.200.890.510.070.140.040.04<0.0001
SAAr0.14−0.03−0.110.120.070.140.160.35
p0.020.640.060.040.240.010.01<0.0001
IL-17Ar0.140.170.100.480.480.010.040.10
p0.010.0030.09<0.0001<0.00010.910.470.10
IL-17Fr0.120.170.120.490.53−0.0030.050.05
p0.030.0040.04<0.0001<0.00010.960.370.38
IL-22r−0.030.120.110.460.450.080.080.14
p0.610.040.07<0.0001<0.00010.180.160.01
TNFαr0.110.090.030.190.230.070.120.13
p0.060.130.620.001<0.00010.240.040.02
IL-6r0.130.01−0.070.080.090.150.200.36
p0.030.800.260.150.120.010.001<0.0001
IFN-γr0.04−0.03−0.040.090.090.060.060.08
p0.530.570.470.120.130.320.310.14
sICAM-1r0.040.120.090.090.100.060.090.15
p0.470.050.130.100.100.300.110.01
sVCAM-1r0.080.060.010.010.000040.0040.040.08
p0.150.280.810.881.00.940.470.19
CCL2 (MCP-1)r0.090.130.060.170.130.190.170.18
p0.120.020.280.0030.030.0010.0030.002
CCL22 (MDC)r0.010.060.080.370.370.080.040.07
p0.900.300.19<0.0001<0.00010.170.460.22
CCL4 (MIP-1β)r0.02−0.01−0.01−0.03−0.06−0.06−0.06−0.06
p0.730.800.900.570.320.300.310.31
IL-8r−0.020.040.070.160.20.120.090.13
p0.670.440.260.0040.0010.040.130.02
YKL-40r0.140.110.040.140.130.120.160.31
p0.020.060.520.020.020.030.007<0.0001
  • Significance is defined by p<0.05 and fold change ≥1.4 (shown in bold).

  • BSA, body surface area; CRP, C reactive protein; DAS28, 28 joint Disease Activity Score; IFN γ, interferon γ; IL, interleukin; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; r, correlation coefficient; SAA, serum amyloid A; TNF, tumour necrosis factor.